$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2021 Q3 Form 10-Q Financial Statement

#000155837021013223 Filed on October 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $38.30K $79.06K
YoY Change -51.56% -28.45%
% of Gross Profit
Research & Development $186.4K $249.5K
YoY Change -25.28% -16.76%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $224.7K $328.5K
YoY Change -31.6% -19.91%
Operating Profit -$224.7K -$328.5K
YoY Change -31.6%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$224.7K -$328.5K
YoY Change -31.6% -19.91%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$224.7K -$328.5K
YoY Change -31.6% -19.91%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$1.710K -$2.499K
COMMON SHARES
Basic Shares Outstanding 131.4M
Diluted Shares Outstanding 131.4M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $900.00 $1.710K
YoY Change -47.37% 54.05%
Cash & Equivalents $904.00 $1.711K
Short-Term Investments
Other Short-Term Assets $940.00 $1.250K
YoY Change -24.8%
Inventory
Prepaid Expenses $936.00
Receivables
Other Receivables
Total Short-Term Assets $1.840K $2.960K
YoY Change -37.84% 166.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.840K $2.960K
Total Long-Term Assets $0.00 $0.00
Total Assets $1.840K $2.960K
YoY Change -37.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.26K $86.14K
YoY Change -77.64%
Accrued Expenses $10.41K $118.2K
YoY Change -91.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.67K $204.4K
YoY Change -85.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $29.67K $204.4K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $29.67K $204.4K
YoY Change -85.48%
SHAREHOLDERS EQUITY
Retained Earnings -$125.4M
YoY Change
Common Stock $125.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$27.83K -$201.4K
YoY Change
Total Liabilities & Shareholders Equity $1.840K $2.960K
YoY Change -37.84%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$224.7K -$328.5K
YoY Change -31.6% -19.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$87.40K -$137.3K
YoY Change -36.35% -5.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 87.71K 139.0K
YoY Change -36.9% -3.51%
NET CHANGE
Cash From Operating Activities -87.40K -137.3K
Cash From Investing Activities
Cash From Financing Activities 87.71K 139.0K
Net Change In Cash 310.0 1.700K
YoY Change -81.76% -185.0%
FREE CASH FLOW
Cash From Operating Activities -$87.40K -$137.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
dei Entity Central Index Key
EntityCentralIndexKey
0000724445
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
dei Security Exchange Name
SecurityExchangeName
NONE
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-08-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-23425
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
131449
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
131449
dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
335-5697
dei Security12b Title
Security12bTitle
None
dei Trading Symbol
TradingSymbol
BZYR
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
904
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
936
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
894
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1840
CY2021Q1 us-gaap Assets Current
AssetsCurrent
956
CY2021Q3 us-gaap Assets
Assets
1840
CY2021Q1 us-gaap Assets
Assets
956
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
19260
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
32512
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10411
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14287
CY2021Q3 us-gaap Liabilities
Liabilities
29671
CY2021Q1 us-gaap Liabilities
Liabilities
46799
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125243548
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124684535
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125402828
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124861827
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-27831
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1840
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
956
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
186417
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
249481
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38301
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
79059
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
224718
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
328540
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-224718
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224718
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-27831
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-152587
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-328540
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-224718
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-328540
CY2021Q3 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2020Q3 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224718
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-328540
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131448444
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131448444
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
418363
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
589166
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
122638
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
197344
us-gaap Operating Expenses
OperatingExpenses
541001
us-gaap Operating Expenses
OperatingExpenses
786510
us-gaap Operating Income Loss
OperatingIncomeLoss
-541001
us-gaap Operating Income Loss
OperatingIncomeLoss
-786510
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-541001
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-786510
us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-541001
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-786510
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131448444
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131448444
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
84967
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
215926
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-61233
CY2021Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
87717
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
170403
CY2020Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
83317
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
281978
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-457970
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-245262
CY2020Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
139017
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
233399
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-328540
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-201386
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-541001
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-786510
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
386329
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
515377
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
42
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18439
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13252
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25335
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3876
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6573
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-171842
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-220786
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
172684
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
222334
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
172684
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
222334
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
842
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1548
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
904
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1711
CY2021Q3 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
bzyr Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
1
us-gaap Revenues
Revenues
0
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
10248
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3783
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-10248
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168582
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-47191
CY2020Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-68993
CY2021Q3 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
47191
CY2020Q3 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
68993
CY2021Q3 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-7015
CY2020Q3 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-9214
CY2021Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7015
CY2020Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9214
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-113610
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-165167
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
113610
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
165167
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3783
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
78948

Files In Submission

Name View Source Status
0001558370-21-013223-index-headers.html Edgar Link pending
0001558370-21-013223-index.html Edgar Link pending
0001558370-21-013223.txt Edgar Link pending
0001558370-21-013223-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210831.xsd Edgar Link pending
tmb-20210831x10q.htm Edgar Link pending
tmb-20210831x10q_htm.xml Edgar Link completed
tmb-20210831xex31d1.htm Edgar Link pending
tmb-20210831xex31d2.htm Edgar Link pending
tmb-20210831xex32d1.htm Edgar Link pending
tmb-20210831xex32d2.htm Edgar Link pending
tmb-20210831_cal.xml Edgar Link unprocessable
tmb-20210831_def.xml Edgar Link unprocessable
tmb-20210831_lab.xml Edgar Link unprocessable
tmb-20210831_pre.xml Edgar Link unprocessable